Form 4: BIODESIX Officer's Stock Transactions Reported

BIODESIX Chief Development Officer Gary Pestano reported the vesting of restricted stock units and a subsequent sale of shares to cover tax obligations.

Summary

• Gary Pestano, Chief Development Officer of BIODESIX INC (BDSX), reported changes in his beneficial ownership of company securities.
• On February 9, 2026, 1,481 shares of common stock were acquired, primarily due to the vesting of Restricted Stock Units (RSUs).
• Following this acquisition, Pestano's direct beneficial ownership of common stock was 9,927 shares.
• On February 10, 2026, 540 shares of common stock were sold at a weighted average price of $10.0841 per share, with prices ranging from $9.94 to $10.21.
• The sale of these 540 shares was an automatic 'sell to cover' transaction to satisfy tax obligations upon RSU vesting.
• After these transactions, Pestano's direct beneficial ownership of common stock is 9,387 shares.
• On February 9, 2026, 68 Restricted Stock Units (RSUs) vested, completing a series of sixteen successive quarterly installments that began on February 8, 2022.
• Also on February 9, 2026, 1,413 Restricted Stock Units (RSUs) vested as part of a series of four successive equal annual installments that began on February 8, 2023. Following this vesting, 1,412 RSUs of this type remain outstanding.
• All RSU numbers mentioned have been adjusted to reflect a one-for-twenty reverse stock split that became effective on September 15, 2025.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, reflecting standard executive compensation practices rather than a discretionary investment decision or a change in company fundamentals.

Positives

• Vesting of 1,481 Restricted Stock Units (RSUs) on February 9, 2026, converting into common stock, represents a realization of executive compensation.

Negatives

• Disposition of 540 common shares on February 10, 2026, reduces the Chief Development Officer's direct beneficial ownership, although this was for tax purposes related to RSU vesting.

Future Outlook

NA

Industry Context

StockSavvy.ai notes that routine insider transactions like 'sell to cover' are common and generally do not signal a change in management's confidence in the company's prospects, especially when tied to pre-scheduled vesting events. Such transactions are typically part of executive compensation plans.

Stakeholder Impact

• Shareholders: No direct impact on company operations or strategy; reflects routine executive compensation.
• Employees: No direct impact.

Key Dates

Recommendation

This Form 4 filing details routine insider transactions related to RSU vesting and tax-related sales, which are common and do not provide new fundamental information to warrant a change in investment recommendation. The transactions are expected and do not indicate a shift in the company's prospects or management's confidence.

Keywords

BIODESIX, BDSX, Form 4, Insider Transaction, RSU Vesting, Stock Sale, Gary Pestano, Chief Development Officer, Common Stock, Reverse Stock Split